Optinose Announces Reporting Date for Second Quarter 2022 Financial Results
Optinose (NASDAQ:OPTN) will report its second quarter 2022 financial results on August 11, 2022, prior to market open. The conference call for discussing these results and corporate updates is scheduled for 8:00 a.m. Eastern Time on the same day. Participants can join the call via webcast or by registering for a telephone connection. A replay of the event will be available on the company's website for 60 days. For more information about Optinose and its focus on ENT and allergy treatments, visit www.optinose.com.
- Scheduled earnings call may indicate proactive communication with investors.
- Focus on ENT and allergy specialists targets a specific and potentially lucrative market.
- None.
Conference Call and Webcast to be held August 11, 2022, at 8:00 a.m. Eastern Time
YARDLEY, Pa., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the second quarter 2022 and corporate updates, before market open on Thursday, August 11, 2022.
Company to Host Conference Call
Members of the Company’s leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 8:00 a.m. Eastern Time on Thursday, August 11, 2022.
Participants may access the conference call live via webcast by visiting the Investors section of Optinose’s website at http://ir.optinose.com/presentations. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a personal PIN that can be used to access the call. In addition, a replay of the webcast will be available on the Company website for 60 days following the event.
About Optinose
Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.
Optinose Investor Contact
Jonathan Neely
jonathan.neely@optinose.com
267.521.0531
FAQ
When will Optinose release its Q2 2022 financial results?
What time is the Optinose conference call for Q2 2022 results?
How can I participate in the Optinose conference call?
Is there a replay available for the Optinose conference call?
